This conference has been deferred to 2023 due to the ongoing impact of the COVID-19 pandemic. Please check back soon for the 2023 schedule.
A major focus of the conference will be studies relying on high dimensional profiling and spatial organization of vascular and immune cells in the vessel wall, as well as systems and machine learning approaches to link emerging data to study the atherosclerotic plaque as a whole entity, rather than studying each cell type individually. We will discuss new molecular pathways regulating vascular and immune cell function, mechanisms of atherosclerosis regression, immunometabolism, clonal hematopoiesis and genetics of atherosclerosis. We continue to connect traditionally isolated research fields that are related to atherosclerosis, including complications of atherosclerosis such as diabetes, myocardial infarction, stroke and neurodegeneration. We propose to address, among others, the following questions: What are the origins of vascular and immune cells in the atherosclerotic plaque—do they reprogram? How is the metabolic profile of vascular and immune cells changed in the setting of atherosclerosis? Can we find therapies to regress atherosclerotic plaques and promote resolution of vascular inflammation? Can we modulate new targets identified in the setting of obesity and Type 2 diabetes so as to reduce cardiovascular risk in those patients? Can we vaccinate against atherosclerosis and/or retrain the immune system to prevent atherosclerosis? How do microRNA and other novel non-coding RNAs influence cell function within the atherosclerotic plaque and can they be targeted therapeutically? How are the genetics of atherosclerosis informing discovery and treatment? What is the future of gene editing in cardiovascular disease?